# A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard Chemotherapy

> **NCT04044222** · PHASE3 · UNKNOWN · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 240 (estimated)

## Conditions studied

- Classic Hodgkin's Lymphoma

## Interventions

- **BIOLOGICAL:** Sintilimab
- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **DRUG:** Ifosfamide
- **DRUG:** Placebo
- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **DRUG:** Ifosfamide

## Key facts

- **NCT ID:** NCT04044222
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-21
- **Primary completion:** 2023-07-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2022-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04044222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04044222, "A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard Chemotherapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04044222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*